open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Get Citation

Erlotinib targeted therapy in patient with advanced lung adenocarcinoma

Bożena Weryńska, Irena Porębska, Monika Kosacka, Renata Jankowska

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23

Abstract

Lung cancer is the most common cancer in men and the third most common type of cancer after breast and colon cancer in women. The prognosis for this cancer is unfavorable and die each year in Poland about 22.000 people. The introduction of targeted therapy represents a significant advance in the treatment of advanced lung cancer. It gives an opportunity to extend the time to disease progression and is associated with fewer side effects compared to the classic chemotherapy. The efficacy of this therapy in tumors without a mutation of this type is not satisfactory. We present a case of a patient with advanced adenocarcinoma of the lung, which was treated with erlotinib. This treatment allowed for the maintenance of stable disease for 31 months while maintaining a good quality of life and continue working.

Abstract

Lung cancer is the most common cancer in men and the third most common type of cancer after breast and colon cancer in women. The prognosis for this cancer is unfavorable and die each year in Poland about 22.000 people. The introduction of targeted therapy represents a significant advance in the treatment of advanced lung cancer. It gives an opportunity to extend the time to disease progression and is associated with fewer side effects compared to the classic chemotherapy. The efficacy of this therapy in tumors without a mutation of this type is not satisfactory. We present a case of a patient with advanced adenocarcinoma of the lung, which was treated with erlotinib. This treatment allowed for the maintenance of stable disease for 31 months while maintaining a good quality of life and continue working.

Get Citation

Keywords

lung cancer, targeted therapy, erlotinib, EGFR

About this article
Title

Erlotinib targeted therapy in patient with advanced lung adenocarcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

61-66

Published online

2015-03-23

Keywords

lung cancer
targeted therapy
erlotinib
EGFR

Authors

Bożena Weryńska
Irena Porębska
Monika Kosacka
Renata Jankowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl